CV6 to Present Details of Ongoing Phase 1a Clinical Trial at 2024 ASCO Annual Meeting

Belfast, UK, 10 May 2024 – CV6 Therapeutics (‘CV6’) is a clinical-stage drug development company targeting Uracil-DNA biology to transform the treatment of cancer and inflammatory diseases. CV6 will be presenting details of their ongoing CV6-168 Phase 1a clinical trial at the 2024 ASCO Annual Meeting to be held at McCormick Pace in Chicago, USA on May 31^st to June 4^th.

Details of the CV6-168 Phase 1a trial will be presented as part of the Trials in Progress poster session in:

– McCormick Place, Chicago
– Hall A
– June 1^st between 9 and 12 local time (CDT)
– Poster abstract number: TPS3170
– Poster Board Number:  310A

CV6-168 is a first-in-class specific DNA uracilation agent that selectively targets the enzyme dUTPase and induces cancer cell DNA uracilation when used in combination with the thymidylate synthase inhibitor class of standard-of-care therapies (5-FU and pemetrexed) resulting in cancer cell death while simultaneously stimulating the immune system.

The poster will present details of the UK multi-centre Phase 1a clinical trial that is now actively recruiting across four leading cancer hospitals that form part of the UK Experimental Cancer Medicine Centre (ECMC) network: Belfast, Glasgow, Newcastle, and the Royal Marsden in London.

The Phase 1a trial is evaluating CV6-168 in combination with infusional 5-FU and folinic acid to treat advanced malignancies. Initially, the trial will focus on safety, pharmacokinetics, identifying optimal dosing levels, and assessing initial indications of anti-cancer activity in up to 51 patients (ISRCTN12434145).

Details of the trial will be presented as part of the ‘Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology’ track within the “Trials in Progress” poster session. The poster will be presented by Prof. Vicky Coyle, Principal Investigator of the lead site in Belfast and Prof. Richard Wilson from the Glasgow site and the trial Chief Investigator. Also in attendance will be Dr. Robert (Bob) Ladner, CEO and Founder of the trial sponsor, CV6 Therapeutics.

Founded in 1964, the American Society of Clinical Oncology is the world’s leading professional organization for physicians and oncology professionals caring for and improving the lives of people with cancer. The ASCO Annual Meeting is the largest gathering of these professionals in the world.